Integrating transcriptomics with metabolic modeling predicts biomarkers and drug targets for Alzheimer's disease

Keyphrases

• Altered Metabolism 20%
• Alzheimer's Disease 100%
• Alzheimer's Disease Diagnosis 20%
• Alzheimer's Disease Pathology 40%
• Alzheimer's Disease Patient 20%
• Carnitine Shuttle 20%
• Cerebral Metabolism 20%
• Disease Proteomics 20%
• Drug Target 100%
• Folate Metabolism 20%
• Genome-scale 20%
• Metabolic 40%
• Metabolic Alterations 40%
• Metabolic Biomarkers 40%
• Metabolic Drugs 20%
• Metabolic Model 20%
• Metabolic Modeling 100%
• Metabolic Pathway 40%
• Metabolomics Data 20%
• Mitochondrial Transport 20%
• Modeling Method 20%
• Network Applications 20%
• Prostaglandin D2 (PGD2) 20%
• Proteomics Data 20%
• Steroid Metabolism 20%
• Succinate 20%
• Transcriptomic Data 20%
• Transcriptomics 100%
• Vitamin D Metabolism 20%
• Wide-view 20%

Biochemistry, Genetics and Molecular Biology

• Brain Metabolism 50%
• Carnitine Shuttle 50%
• Folate Metabolism 50%
• Metabolic Pathway 100%
• Metabolomics 50%
• Mitochondrial Transport 50%
• Prostaglandin D2 50%
• Proteomics 50%
• Steroid Metabolism 50%
• Transcriptomics 100%
• Vitamin D Metabolism 50%